Form 4: Enanta CSO Granted 110,000 Stock Options

Enanta Pharmaceuticals' Chief Scientific Officer, Or Yat Sun, was granted 110,000 stock options with an exercise price of $13.66.

Summary

• Or Yat Sun, Chief Scientific Officer of Enanta Pharmaceuticals Inc. (ENTA), was granted 110,000 stock options.
• The stock options have an exercise price of $13.66 per share.
• The transaction date for this grant was November 25, 2025.
• These options will become exercisable quarterly in substantially equal installments over four years from the grant date, subject to continued employment.
• The options have an expiration date of November 25, 2035.
• Following this transaction, Or Yat Sun beneficially owns 110,000 derivative securities.

Sentiment

Score: 7

Explanation: The grant of stock options is a standard form of executive compensation, aligning management's interests with shareholder value creation. It is generally viewed as a positive for executive retention and motivation, without indicating any immediate negative operational or financial issues for the company.

Positives

• The grant of stock options aligns the Chief Scientific Officer's financial interests with those of the shareholders, incentivizing long-term performance.
• The compensation structure encourages the executive to contribute to the company's stock price appreciation.

Negatives

• The options do not represent immediate cash value and their ultimate value is dependent on the future stock price exceeding the exercise price.
• The vesting schedule ties the executive to the company for four years, which could be seen as a constraint.

Risks

• The value of the stock options is subject to market fluctuations and the company's stock performance; if the stock price does not rise above the exercise price, the options may expire worthless.
• The exercisability of the options is contingent upon the optionholder's continued employment with Enanta Pharmaceuticals.

Future Outlook

The grant of stock options to a key executive implies a strategic intent to retain talent and incentivize long-term value creation, suggesting management's confidence in the company's future prospects.

Industry Context

The grant of stock options is a common practice in the biotechnology and pharmaceutical industries to compensate and retain key scientific and executive talent. This aligns with standard industry practices for executive incentive compensation.

Comparison to Industry Standards

• Executive stock option grants are a standard component of compensation packages across the biotech and pharmaceutical sectors, similar to practices at companies like Gilead Sciences or Vertex Pharmaceuticals, which frequently use equity incentives to attract and retain top talent.
• The four-year quarterly vesting schedule is typical for executive equity awards, designed to ensure long-term commitment and performance alignment, comparable to vesting schedules observed in major pharmaceutical companies.

Related Party Transactions

• The grant of stock options to Or Yat Sun, the Chief Scientific Officer, constitutes a related party transaction as it involves compensation from the company to an executive officer.

Stakeholder Impact

• Shareholders: Potential positive impact through enhanced executive motivation and alignment of interests, which could lead to increased shareholder value if the company performs well.
• Employees (specifically the Chief Scientific Officer): Direct financial incentive and benefit, fostering retention and commitment to the company's long-term success.

Next Steps

• The Chief Scientific Officer must maintain continued employment for the options to vest according to the quarterly schedule over four years.
• The options may be exercised at any time after vesting and before the expiration date, subject to the terms of the option agreement.

Key Dates

Keywords

Enanta Pharmaceuticals, ENTA, Stock Options, Executive Compensation, Form 4, Insider Transaction, Or Yat Sun, Chief Scientific Officer, Derivative Securities